MedTrace Logo

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

NCT07349277 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-01-20

No results posted yet for this study

Summary

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Conditions

  • Preeclampsia
  • Gestational Hypertension
  • Hypertensive Disorders of Pregnancy

Sponsors & Collaborators

  • Ammar Jassim Abed

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2026-01-30
Completion
2026-04-30

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07349277 on ClinicalTrials.gov